DiappyMed

Founded in 2021 in Montpellier, France, following academic research conducted at Montpellier University Hospital on intelligent insulin dosage tools. In March 2026, the company raised EUR 5 million in a Seed funding round led by Ventech, alongside AFI Ventures, Sofilaro and IRDI Capital Investissement, and announced a strategic partnership with Sanofi; no acquisitions have been publicly disclosed. DiappyMed offers EkiYou, a CE‑marked Class IIb digital therapeutic that provides personalised insulin dose recommendations based on glucose levels, meals and physical activity, and EkiYou Carbs, a carbohydrate‑counting mobile application. These solutions are intended to assist patients and healthcare professionals by supporting functional insulin therapy without replacing medical advice.

DiappyMed generates revenue primarily through the commercialisation of its digital therapeutic solutions within the French healthcare ecosystem. Its revenues are linked to the deployment and use of its applications through healthcare providers, partnerships, and digital health programmes rather than consumer advertising models. The company will use the funding to expand its teams for healthcare professional training, patient support, and research and development.